Compare Manulife Financial Corporation (MFC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Manulife Financial Corporation trades at $44.03 (market cap $72.68B), while Zimmer Biomet Holdings Inc trades at $95.81 (market cap $18.55B). The key difference: Manulife Financial Corporation is far larger — about 3.9× Zimmer Biomet Holdings Inc's market cap, and Manulife Financial Corporation pays the higher dividend (3.1%). Which is the better fit depends on your goals.
| MFC | ZBH | |
|---|---|---|
Market Cap | $72.68B | $18.55B |
Sector | Financials | Health |
52-Week High | $44.77 | $107.71 |
52-Week Low | $30.06 | $79.58 |
Enterprise Value | $67.84B | $25.61B |
Dividend Yield | 3.1% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $44.15, down 0.38% on the day, with a bullish technical signal from moving averages and neutral oscillators. Revenue grew to $53.01B in 2025, with net income of $5.78B, and the company has a strong analyst consensus of 57% buy ratings. Recent Q2 2026 earnings beat expectations, driven by Asia growth and insurance sales, while dividends of $0.49 per share were declared for H1 and H2 2026.
MFC's outlook is positive due to earnings momentum and strategic AI partnerships, but risks include premium valuation and segment volatility. The stock offers steady dividends and growth potential, though investors should monitor execution in wealth management and macroeconomic impacts on insurance demand.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
